The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...

Key Takeaways Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...